Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia

American Journal of Psychiatry

Volumn 166, Issue 6, 2009, Pages 691-701

  Canuso, Carla M ^a   Dirks, Bryan ^b   Carothers, Jennifer ^b   Kosik Gonzalez, Colette ^b   Bossie, Cynthia A ^b   Zhu, Young ^b   Damaraju, C V ^b   Kalali, Amir H ^b   Mahmoud, Ramy ^b  

^a Janssen Pharmaceutica   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PALIPERIDONE; QUETIAPINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RATING SCALE; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 66949121772     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.08040613     Document Type: Article

References (33)

1. Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106:323-330 (Pubitemid 35176874)
2. Patrick V, Levin E, Schleifer S: Antipsychotic polypharmacy: is there evidence for its use? J Psychiatr Pract 2005; 11:248-257
3. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ: Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161:700-706 (Pubitemid 38445515)
4. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M: Efficacy, safety, and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007; 93:117-130 (Pubitemid 46817944)
5. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007; 90:147-161 (Pubitemid 46178537)
6. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A: Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007; 62:1363-1370 (Pubitemid 350180724)
7. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M: Efficacy and tolerability of oral paliperidone extended- release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008; 69:817-829 (Pubitemid 351838691)
8. Conley R, Gupta SK, Sathyan G: Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006; 22:1879-1892 (Pubitemid 44663390)
9. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik- Gonzalez C, Rupnow MF, Bossie CA, Davidson M, Burtea V, Zhu Y, Trivedi JK: A double-blind comparison of risperidone, quetiapine, and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85:254-265 (Pubitemid 43947539)
10. Berwaerts J, Cleton A, van de Vliet I, Chang I, van Hoek P, Prosser J, Eerdekens M: A randomized, open-label, single-center crossover study of the potential effects of paroxetine on the pharmacokinetics of a single dose of paliperidone extended-release tablet in healthy subjects, in New Research Abstracts, American Psychiatric Association 2007 Annual Meeting. Washington, DC, APA, 2007
11. Vermir M, Boom S, Naessens I, Talluri K, Eerdekens M: Absorption, metabolism, and excretion of a single oral dose of 1 mg paliperidone in a population of five healthy male subjects. Eur Neuropsychopharmacol 2005; 15(suppl 3):S648
12. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33 (Pubitemid 29001829)
13. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276 (Pubitemid 18039085)
14. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
15. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538-546 (Pubitemid 28100274)
16. Potkin SG, Gharabawi GM, Greenspan AJ, Rupnow MF, Kosik- Gonzalez C, Remington G, Ruetsch C, Revicki D: Psychometric evaluation of the Readiness for Discharge Questionnaire. Schizophr Res 2005; 80:203-212 (Pubitemid 41713646)
17. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
18. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676 (Pubitemid 19154942)
19. Guy WA: Abnormal Involuntary Movement Scale (AIMS), in ECDEU Assessment Manual for Psychopharmacology. Washington, DC, US Department of Health, Education, and Welfare, 1972, pp 534-537
20. Atypical antipsychotic prescription data for March 2007-February 2008 (MAT February 2008). IMS Health Inc
21. Agency for Healthcare Research and Quality: Welcome to HCUPnet (Healthcare Cost and Utilization Project). http:// hcupnet.ahrq.gov/
22. Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60:1228-1235 (Pubitemid 37494076)
23. Leucht S, Busch R, Hamann J, Kissling W, Kane JM: Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed, and extended. Biol Psychiatry 2005; 57:1543-1549 (Pubitemid 40805384)
24. Janssen B, Weinmann S, Berger M, Gaebel W: Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 2004; 30:1023-1033 (Pubitemid 40469534)
25. Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl SM: Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin 2007; 23:2815-2822 (Pubitemid 350146419)
26. Arvanitis LA, Miller BG: Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42:233-246 (Pubitemid 27325811)
27. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54:549-557 (Pubitemid 27258553)
28. Greenspan A, Gharabawi G, Kwentus J: Thyroid dysfunction during treatment with atypical antipsychotics. J Clin Psychiatry 2005; 66:1334-1335 (Pubitemid 41546518)
29. Kelly DL, Conley RR: Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005; 66:80-84
30. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163:185-194 (Pubitemid 44480836)
31. Citrome L, Jaffe A, Levine J, Lindenmayer JP: Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 2005; 66:1512-1516 (Pubitemid 43068688)
32. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223 (Pubitemid 41345943)
33. Woods SW, Gueorguieva RV, Baker CB, Makuch RW: Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry 2005; 62:961-970 (Pubitemid 41248375)